Whole Genome Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Library Preparation, DNA Extraction) Sequencing Type (Large, Small, Phased), Technology (SBS, SMRT, Nanopore, Nanoball) Application, End User ΓÇô Global Forecast to 2032

The growth of this market can be attributed to the declining costs of sequencing, the increasing prevalence of cancer & genetic disorders, the growing utilization of whole genome sequencing in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for whole genome sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of diseases, technological advancements in sequencing products, and government initiatives promoting the use of sequencing in clinical & research applications.

Furthermore, increasing applications of whole genome sequencing, government support for large-scale genomic sequencing projects, and emerging economies are expected to offer significant market growth opportunities.

Increasing Prevalence of Cancer & Genetic Disorders

Whole-genome sequencing is frequently conducted in clinical settings, particularly for genetic diseases and chronic diseases like cancer. In the case of rare genetic diseases where no specific mutations have been observed using other molecular tests, advanced sequencing technologies are used for whole-genome sequencing. The global burden of genetic diseases and cancer is increasing. For instance,

• According to Global Genes, there are more than 10,000 distinct types of genetic and rare diseases, and approximately 80% of rare diseases are genetic.
• According to a WHO report from February 2023, approximately 240,000 newborns die within 28 days of birth, and 170,000 children aged 1 month to 5 years die due to congenital disorders globally.
• According to the World Economic Forum (Switzerland), around 21 million people in China are living with rare diseases.
• According to the National Institutes of Health (NIH), around 20 million people worldwide are affected by sickle cell disease, and approximately 100,000 people in the U.S. are living with the condition.
• According to the International Agency for Research on Cancer (IARC), a specialized agency of the World Health Organization (WHO), cancer incidence is expected to increase from 26.9 million in 2022 to 39.5 million in 2040. Moreover, mortalities due to cancer are estimated to increase from 9.7 million in 2022 to 35 million in 2050. Nearly 70% of the total deaths due to cancer occur in low and middle-income countries.

Thus, the increasing prevalence of cancer genetic disorders is increasing the demand for diagnosis of genetic disorders, which in turn is expected to drive the growth of the whole genome sequencing market.

Technological Advancements in Sequencing Products

Whole genome sequencing allows for the detection of both large and small variants in the genome and facilitates the analysis of an individual’s entire genome. The high resolution provided by WGS enables the identification of genomic variations, including translocations and copy number variations, making it a powerful tool for studying the genetic basis of various health conditions and diseases. While WGS is commonly used to sequence the entire human genome, the advent of next-generation sequencing technology has expanded its applications to include sequencing genomes of several species, such as plants, livestock, and microorganisms related to diseases.

The base-by-base analysis offered by whole genome sequencing further aids in detecting structural rearrangements, allowing the identification of variants in both coding and non-coding regions. This is particularly important, as the interpretation of non-coding variants can be challenging with conventional sequencing methods. As a result, the advantages of whole genome sequencing contribute to its increasing adoption in clinical settings, driving the growth of the whole genome sequencing market.

Government Initiatives Supporting Large-Scale Genomic Sequencing Projects

The availability of advanced sequencing technologies has lowered sequencing costs and significantly reduced the time required for genome sequencing. With the availability of safe and accurate genetic tests, governments around the world aim to promote their use for better healthcare management by investing in genomic research. For instance,

• According to a report of February 2024 by the Commonwealth of Australia, the Genomics Health Futures Mission invested USD 500.1 million in genomic research. This investment aims to deliver better testing, diagnostics, and treatment.

• In October 2023, the Government of Canada invested USD 15 million for creating a Pan-Canadian Genome Library which allows easier sharing of genomic data across the country.
• In December 2022, the Government of U.K invested USD 217 million to boost genomic research.

Thus, such initiatives are expected to offer significant opportunities for the growth of the whole genome sequencing market.

Increasing Applications of Whole Genome Sequencing

Whole genome sequencing allows for the in-depth analysis of gene mutations, aiding in the diagnosis of diseases. It is particularly useful in critical situations where rapid diagnosis is essential. WGS can be employed to uncover the underlying causes of unexplained conditions, including intellectual disabilities, brain abnormalities, developmental delays (such as delays in walking or talking), hearing or vision problems, severe skeletal abnormalities, immune deficiencies, and more.

Moreover, the increasing prevalence of genetic diseases in infants has driven the demand for prenatal screening to prevent congenital disabilities. Whole genome sequencing has proven effective in detecting aneuploidies, microdeletions, and other genetic abnormalities, contributing to efforts to reduce the incidence of congenital disabilities.

By Offering: In 2024, the Consumables Segment to Dominate the Whole Genome Sequencing Market

Based on offering, the whole genome sequencing market is segmented into consumables, sequencing instruments, software, and services. In 2024, the consumables segment is expected to account for the largest share of 70.1% of the whole genome sequencing market. This segment’s large market share is attributed to the recurring use of consumables, continuous advancements in reagents and target enrichment protocols, and the growing adoption of whole genome sequencing in clinical settings, which drives the demand for consumables. Additionally, many companies are focusing on both organic and inorganic strategies to enhance their consumable offerings, further contributing to the segment's largest share.

By Sequencing Type: In 2024, the Large whole-genome sequencing Segment to Dominate the Whole Genome Sequencing Market

Based on sequencing type, the whole genome sequencing market is segmented into large whole-genome sequencing, small whole-genome sequencing, human whole-genome sequencing¸, and other whole-genome sequencing types. In 2024, the large whole genome sequencing segment is expected to account for the largest share of 76.7% of the whole genome sequencing market. This segment’s large market share is attributed to several factors, including the high resolution and base-by-base analysis provided by large whole-genome sequencing, which enables comprehensive genome sequencing for population-level studies. Additionally, whole genome sequencing is increasingly used in tumor analysis, disease research, animal and plant breeding selection, and the identification of common genetic variations, all of which contribute to the segment's largest share.

By Technology: In 2024, the Sequencing by Synthesis Segment to Dominate the whole genome Sequencing Market

Based on technology, the whole genome sequencing market is segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing (SMRT), nanopore sequencing, and DNA nanoball (DNB) sequencing. In 2024, the sequencing by synthesis segment is expected to account for the largest share of 56.5% of the whole genome sequencing market. This segment’s large market share is attributed to the high adoption of sequencing by synthesis technology due to its high accuracy and its capability to support both paired-end and single-read libraries, offering high-resolution genome sequencing.

By Application: In 2024, the Research and Other Applications Segment to Dominate the Whole Genome Sequencing Market

Based on application, the whole genome sequencing market is segmented into research applications and clinical applications. In 2024, the research applications segment is expected to account for the largest share of the whole genome sequencing market. The research applications segment is further sub-segmented into drug discovery, agriculture & animal research, and other applications. This segment’s large market share is attributed to several factors, including the increasing use of whole genome sequencing to identify novel drug targets, the rising demand for gene-based medicines, growing investments in drug research and development, and the expansion of research programs focused on personalized medicine. Additionally, whole genome sequencing is widely used in research to identify specific genes and their sequences. It plays a crucial role in developing targeted therapies, food microbiology, microbiota analysis in the beverage industry, and environmental studies.

By End User: In 2024, the Pharmaceutical & Biotechnology Companies Segment to Dominate the Whole Genome Sequencing Market

Based on end user, the whole genome sequencing market is segmented into pharmaceutical & biotechnology companies, hospitals and diagnostic laboratories, academic institutes & research centers, and other end users. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share is attributed to factors such as increased R&D spending by pharmaceutical and biotechnology companies, the rising incidence of genetic diseases, and the growing adoption of whole genome sequencing in drug development and genetic research. Additionally, the extensive use of advanced sequencing technologies for cancer studies further drives the growth of this segment.

In 2024, North America is expected to account for the largest share of 52.1% of the whole genome sequencing market. The large market share of this region is primarily attributed to the high research investments by pharmaceutical and biopharmaceutical companies, the presence of leading whole genome sequencing providers in the region, high awareness of whole genome sequencing, favorable government initiatives for genomics research applications, growing applications of NGS-based research, declining cost of sequencing, high cancer prevalence, and favorable reimbursement scenario in the region.

However, the market in Asia-Pacific is slated to register the highest growth rate of 16.4% during the forecast period. The region is becoming an increasingly active market for healthcare product manufacturers and service providers due to improving healthcare infrastructure. Asia-Pacific’s growing population is a key driver for the healthcare and pharmaceutical sectors, attracting significant investments from both market players and government organizations. Countries like China, Japan, India, and Singapore are striving to enhance their competitiveness in the global biotech market, leading to increased research and development activities in the next-generation sequencing market. These factors are contributing to the growth of this regional market.

The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years (2021–2024). The key players operating in the whole genome sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S) Agilent Technologies, Inc. (U.S), Pacific Biosciences of California Inc. (U.S), Danaher Corporation (U.S), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K),MGI Tech Co., Ltd. (China), Beijing Genomics Institute (BGI) (China)

Whole Genome Sequencing Industry Overview: Latest Developments from Key Industry Players

• In May 2024, QIAGEN N.V. (Netherlands) launched the QIAseq Multimodal DNA/RNA Library Kit. The kit enables the preparation of RNA and DNA libraries for NGS, which includes whole transcriptome sequencing (WTS) and whole genome sequencing (WGS).

• In November 2023, QIAGEN N.V. (Netherlands) launched a research workflow that includes high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis.
• In October 2023, Pacific Biosciences of California Inc. (U.S.) launched the Pacific Biosciences of California WGS variant pipeline. It is a complete, standardized computational method for HiFi Whole Genome Sequencing (WGS) data analysis.
• In March 2023, Illumina, Inc. (U.S.) launched Connected Insights, a cloud-based software for tertiary analysis of clinical next-generation sequencing data, including somatic oncology applications, whole genome sequencing for rare

diseases, and reduced turnaround time of clinical reporting via integration of third-party knowledge bases.

• In July 2022, Beijing Genomics Institute (BGI) (China), BGI Genomics partnered with the Serbian Genome Sequencing and Bioinformatics Center to enhance and develop the center's whole exome sequencing (WES), whole genome sequencing (WGS), and genomic analysis capabilities.